(STZ) Constellation Brands - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US21036P1084
Stock: Beer, Wine, Spirits
Total Rating 42
Risk 85
Buy Signal -0.53
| Risk 5d forecast | |
|---|---|
| Volatility | 32.2% |
| Relative Tail Risk | -5.87% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.64 |
| Alpha | -27.15 |
| Character TTM | |
|---|---|
| Beta | 0.237 |
| Beta Downside | -0.259 |
| Drawdowns 3y | |
|---|---|
| Max DD | 51.28% |
| CAGR/Max DD | -0.19 |
EPS (Earnings per Share)
Revenue
Description: STZ Constellation Brands February 26, 2026
Constellation Brands Inc. (NYSE: STZ) is a diversified alcoholic-beverage company that produces, imports, markets and sells a portfolio of beer, wine and spirits across the United States, Canada, Mexico, New Zealand and Italy. Its flagship beer lineup includes Corona, Modelo and Pacifico, while its wine brands feature Robert Mondavi, Kim Crawford and Ruffino, and its spirits portfolio includes High West, Casa Noble and SVEDKA.
In FY 2023 the company generated $9.6 billion in net sales, up 6% year-over-year, with an adjusted earnings-per-share of $5.55 and free cash flow of $1.9 billion, supporting a dividend yield of roughly 7.8% and a payout ratio near 80%.
Key sector drivers remain strong premiumization trends and the continued expansion of low-calorie and hard-seltzer categories, which have delivered double-digit volume growth for Corona Hard Seltzer. Additionally, resilient consumer spending in the U.S. and favorable exchange-rate dynamics in emerging markets are bolstering margin expansion for the Distillers & Vintners sub-industry.
For a deeper quantitative view, you might want to explore ValueRay’s analyst tools.
Headlines to watch out for
- Mexican beer portfolio drives revenue growth
- Wine and spirits segment faces competitive pressures
- Input costs for grains and packaging impact margins
- Regulatory changes in alcohol distribution pose risks
- Consumer discretionary spending influences premium beverage sales
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 1.11b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 0.66 > 1.0 |
| NWC/Revenue: 7.84% < 20% (prev 3.34%; Δ 4.50% < -1%) |
| CFO/TA 0.12 > 3% & CFO 2.70b > Net Income 1.11b |
| Net Debt (10.51b) to EBITDA (2.47b): 4.25 < 3 |
| Current Ratio: 1.34 > 1.5 & < 3 |
| Outstanding Shares: last quarter (174.6m) vs 12m ago -3.93% < -2% |
| Gross Margin: 51.96% > 18% (prev 0.50%; Δ 5.15k% > 0.5%) |
| Asset Turnover: 42.18% > 50% (prev 44.65%; Δ -2.47% > 0%) |
| Interest Coverage Ratio: 5.47 > 6 (EBITDA TTM 2.47b / Interest Expense TTM 376.4m) |
Altman Z'' 3.92
| A: 0.03 (Total Current Assets 2.91b - Total Current Liabilities 2.17b) / Total Assets 21.68b |
| B: 0.62 (Retained Earnings 13.55b / Total Assets 21.68b) |
| C: 0.09 (EBIT TTM 2.06b / Avg Total Assets 22.24b) |
| D: 0.99 (Book Value of Equity 13.55b / Total Liabilities 13.68b) |
| Altman-Z'' Score: 3.92 = AA |
Beneish M -3.27
| DSRI: 0.92 (Receivables 708.3m/836.2m, Revenue 9.38b/10.18b) |
| GMI: 0.97 (GM 51.96% / 50.18%) |
| AQI: 0.97 (AQ_t 0.46 / AQ_t-1 0.48) |
| SGI: 0.92 (Revenue 9.38b / 10.18b) |
| TATA: -0.07 (NI 1.11b - CFO 2.70b) / TA 21.68b) |
| Beneish M-Score: -3.27 (Cap -4..+1) = AA |
What is the price of STZ shares?
As of March 14, 2026, the stock is trading at USD 149.96 with a total of 1,504,248 shares traded.
Over the past week, the price has changed by +2.51%, over one month by +0.56%, over three months by +5.33% and over the past year by -15.17%.
Over the past week, the price has changed by +2.51%, over one month by +0.56%, over three months by +5.33% and over the past year by -15.17%.
Is STZ a buy, sell or hold?
Constellation Brands has received a consensus analysts rating of 3.96.
Therefore, it is recommended to buy STZ.
- StrongBuy: 9
- Buy: 7
- Hold: 10
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the STZ price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 170.7 | 13.9% |
| Analysts Target Price | 170.7 | 13.9% |
STZ Fundamental Data Overview March 12, 2026
P/E Trailing = 23.5991
P/E Forward = 11.8765
P/S = 2.7848
P/B = 3.35
P/EG = 5.4559
Revenue TTM = 9.38b USD
EBIT TTM = 2.06b USD
EBITDA TTM = 2.47b USD
Long Term Debt = 10.29b USD (from longTermDebt, last quarter)
Short Term Debt = 378.7m USD (from shortTermDebt, last quarter)
Debt = 10.66b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 10.51b USD (from netDebt column, last quarter)
Enterprise Value = 36.64b USD (26.13b + Debt 10.66b - CCE 152.4m)
Interest Coverage Ratio = 5.47 (Ebit TTM 2.06b / Interest Expense TTM 376.4m)
EV/FCF = 20.79x (Enterprise Value 36.64b / FCF TTM 1.76b)
FCF Yield = 4.81% (FCF TTM 1.76b / Enterprise Value 36.64b)
FCF Margin = 18.78% (FCF TTM 1.76b / Revenue TTM 9.38b)
Net Margin = 11.83% (Net Income TTM 1.11b / Revenue TTM 9.38b)
Gross Margin = 51.96% ((Revenue TTM 9.38b - Cost of Revenue TTM 4.51b) / Revenue TTM)
Gross Margin QoQ = 53.23% (prev 52.80%)
Tobins Q-Ratio = 1.69 (Enterprise Value 36.64b / Total Assets 21.68b)
Interest Expense / Debt = 0.81% (Interest Expense 86.6m / Debt 10.66b)
Taxrate = 17.41% (110.1m / 632.3m)
NOPAT = 1.70b (EBIT 2.06b * (1 - 17.41%))
Current Ratio = 1.34 (Total Current Assets 2.91b / Total Current Liabilities 2.17b)
Debt / Equity = 1.38 (Debt 10.66b / totalStockholderEquity, last quarter 7.71b)
Debt / EBITDA = 4.25 (Net Debt 10.51b / EBITDA 2.47b)
Debt / FCF = 5.96 (Net Debt 10.51b / FCF TTM 1.76b)
Total Stockholder Equity = 7.34b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.99% (Net Income 1.11b / Total Assets 21.68b)
RoE = 15.12% (Net Income TTM 1.11b / Total Stockholder Equity 7.34b)
RoCE = 11.68% (EBIT 2.06b / Capital Employed (Equity 7.34b + L.T.Debt 10.29b))
RoIC = 9.24% (NOPAT 1.70b / Invested Capital 18.41b)
WACC = 5.02% (E(26.13b)/V(36.79b) * Re(6.79%) + D(10.66b)/V(36.79b) * Rd(0.81%) * (1-Tc(0.17)))
Discount Rate = 6.79% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -2.63%
[DCF] Terminal Value 86.77% ; FCFF base≈1.74b ; Y1≈1.82b ; Y5≈2.11b
[DCF] Fair Price = 299.9 (EV 62.51b - Net Debt 10.51b = Equity 52.00b / Shares 173.4m; r=5.90% [WACC]; 5y FCF grow 4.94% → 2.90% )
EPS Correlation: 42.66 | EPS CAGR: 7.05% | SUE: 1.91 | # QB: 2
Revenue Correlation: 10.95 | Revenue CAGR: 1.49% | SUE: 1.48 | # QB: 1
EPS next Quarter (2026-05-31): EPS=3.35 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=14
EPS next Year (2027-02-28): EPS=12.36 | Chg7d=+0.000 | Chg30d=+0.003 | Revisions Net=-4 | Growth EPS=+6.5% | Growth Revenue=+0.4%
[Analyst] Revisions Ratio: -0.08 (6 Up / 7 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.7% (Discount Rate 7.9% - Earnings Yield 4.2%)
[Growth] Growth Spread = -9.5% (Analyst -5.8% - Implied 3.7%)
P/E Forward = 11.8765
P/S = 2.7848
P/B = 3.35
P/EG = 5.4559
Revenue TTM = 9.38b USD
EBIT TTM = 2.06b USD
EBITDA TTM = 2.47b USD
Long Term Debt = 10.29b USD (from longTermDebt, last quarter)
Short Term Debt = 378.7m USD (from shortTermDebt, last quarter)
Debt = 10.66b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 10.51b USD (from netDebt column, last quarter)
Enterprise Value = 36.64b USD (26.13b + Debt 10.66b - CCE 152.4m)
Interest Coverage Ratio = 5.47 (Ebit TTM 2.06b / Interest Expense TTM 376.4m)
EV/FCF = 20.79x (Enterprise Value 36.64b / FCF TTM 1.76b)
FCF Yield = 4.81% (FCF TTM 1.76b / Enterprise Value 36.64b)
FCF Margin = 18.78% (FCF TTM 1.76b / Revenue TTM 9.38b)
Net Margin = 11.83% (Net Income TTM 1.11b / Revenue TTM 9.38b)
Gross Margin = 51.96% ((Revenue TTM 9.38b - Cost of Revenue TTM 4.51b) / Revenue TTM)
Gross Margin QoQ = 53.23% (prev 52.80%)
Tobins Q-Ratio = 1.69 (Enterprise Value 36.64b / Total Assets 21.68b)
Interest Expense / Debt = 0.81% (Interest Expense 86.6m / Debt 10.66b)
Taxrate = 17.41% (110.1m / 632.3m)
NOPAT = 1.70b (EBIT 2.06b * (1 - 17.41%))
Current Ratio = 1.34 (Total Current Assets 2.91b / Total Current Liabilities 2.17b)
Debt / Equity = 1.38 (Debt 10.66b / totalStockholderEquity, last quarter 7.71b)
Debt / EBITDA = 4.25 (Net Debt 10.51b / EBITDA 2.47b)
Debt / FCF = 5.96 (Net Debt 10.51b / FCF TTM 1.76b)
Total Stockholder Equity = 7.34b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.99% (Net Income 1.11b / Total Assets 21.68b)
RoE = 15.12% (Net Income TTM 1.11b / Total Stockholder Equity 7.34b)
RoCE = 11.68% (EBIT 2.06b / Capital Employed (Equity 7.34b + L.T.Debt 10.29b))
RoIC = 9.24% (NOPAT 1.70b / Invested Capital 18.41b)
WACC = 5.02% (E(26.13b)/V(36.79b) * Re(6.79%) + D(10.66b)/V(36.79b) * Rd(0.81%) * (1-Tc(0.17)))
Discount Rate = 6.79% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -2.63%
[DCF] Terminal Value 86.77% ; FCFF base≈1.74b ; Y1≈1.82b ; Y5≈2.11b
[DCF] Fair Price = 299.9 (EV 62.51b - Net Debt 10.51b = Equity 52.00b / Shares 173.4m; r=5.90% [WACC]; 5y FCF grow 4.94% → 2.90% )
EPS Correlation: 42.66 | EPS CAGR: 7.05% | SUE: 1.91 | # QB: 2
Revenue Correlation: 10.95 | Revenue CAGR: 1.49% | SUE: 1.48 | # QB: 1
EPS next Quarter (2026-05-31): EPS=3.35 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=-1 | Analysts=14
EPS next Year (2027-02-28): EPS=12.36 | Chg7d=+0.000 | Chg30d=+0.003 | Revisions Net=-4 | Growth EPS=+6.5% | Growth Revenue=+0.4%
[Analyst] Revisions Ratio: -0.08 (6 Up / 7 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.7% (Discount Rate 7.9% - Earnings Yield 4.2%)
[Growth] Growth Spread = -9.5% (Analyst -5.8% - Implied 3.7%)